Global stock

NYSEUSD

Waters Corp.

WAT

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

59/ 100

Overall score·WAT

Current price

455.98USD

26/10/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Valuace působí napjatě: P/E 109 a EV/EBITDA 32,6 jsou vysoké, přestože forward P/E klesá na 26,1. Růst tržeb je mimořádně vysoký, ale může být ovlivněn jednorázovými či akvizičními faktory; ziskovost podle uvedených marží a ROE zaostává. Momentum je příznivé, protože cena převyšuje 50denní i 200denní průměr.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 55%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Financial results

Financial results·WAT

M USD

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·WAT

Net marginEBITDA marginDashed = estimate

Net margin

+20.3 %

FY 2025 · reported

EBITDA margin

+32.6 %

FY 2026 · estimate

Net margin

+3.6 %

last 12 months

Operating margin

+9.4 %

last 12 months

ROE

+1.9 %

last 12 months

FY = fiscal year · TTM = trailing 12 months

§ Context and events

Management

Udit Batra je prezident, CEO a člen představenstva; Amol Chaubal působí jako senior viceprezident a CFO. Vedení stojí v čele společnosti zaměřené na analytické přístroje, diagnostiku a související laboratorní technologie. Jianqing Y. Bennett vede divizi Waters Advanced Diagnostics a Mark Gladwell odpovídá za globální provoz.

Articles about Waters Corp., in Czech (1)

Waters získává schválení FDA pro systém BD BACTEC FXI, rozšiřuje možnosti diagnostiky infekcí

Waters oznámil získání schválení od FDA pro svůj nový systém BD BACTEC FXI, který umožňuje rozšířený přístup k diagnostice infekcí v krvi. Tato certifikace může posílit pozici firmy na trhu zdravotnických technologií a zlepšit možnosti detekce závažných bakteriálních a plísňových infekcí.

10 June 2026· 3 min

§ Upcoming results

3 November 2026

in 7 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Waters Corp. (WAT)?

Waters Corp. (WAT) is a global stock traded on NYSE. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Waters Corp. price today?

As of 26 October 2026, Waters Corp. trades at about 455.98 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Waters Corp.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Waters Corp. pay a dividend?

Waters Corp. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Waters Corp. a good investment in 2026?

Our AI signal currently rates Waters Corp. as slightly positive (score 66/100). Financial health comes out at 59/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Waters Corp.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 7 days

On 3 November 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

Fresh news

Signal 27/10, 03:02

Waters za šest měsíců posílila o 51,7 % na 454,91 USD; zpráva zároveň upozorňuje na pokles ROIC. Růst podpoří výhled, pokud se investice začnou zhodnocovat.

Růst ceny za 7 i 30 dní a rostoucí trend podporují krátkodobý výhled, RSI 66 a vysoká volatilita ale zvyšují riziko výkyvů. Silný ROIC a očekávaný růst tržeb vyvažuje jeho nedávný pokles.

Risks: Pokračující pokles ROIC nebo obrat rostoucího cenového trendu by tento výhled oslabil.

More about the signal

Risks: Pokračující pokles ROIC nebo obrat rostoucího cenového trendu by tento výhled oslabil.

Signal history· 2

23/1018:0271 · Strongly positive
Labcorp uzavřel partnerství s Waters, aby rozšířil přístup k FDA schválenému HPV testování; dopad podpoří širší využití, zatímco náběh je plánován až na konec roku 2026.
21/1009:0260 · Slightly positive
Waters představila propojení AI pro LC‑MS a spolupracuje s Quest Diagnostics na domácím HPV screeningu; dopad posílí, pokud se řešení promítnou do širšího využití.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 17 of 18

Valuation score

0/ 6

4/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

99% above the 1-year low (283.3 USD to 457.5 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 109.4 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 1.6; a lower value means cheaper growth.

6. Analyst price target

0.5% vs. the current price, 23 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

456.0 USD

Low 349.0 USDHigh 530.0 USD

Current priceAverage: 458.2 USD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

+0.5%

Average target 458.2 USD vs. price 456.0 USD.

Analyst consensus

Target range

349.0 USD - 530.0 USD

Coverage

23 analysts

Analyst consensus

1.6 / 5

Changes 180 d

+3 / -0

EPS next year

13.4%

Revenue next year

10.3%

Valuation multiples

109.4

26.1

2.8

9.1

32.6

1.6

52-week range99% above the low

283.3 USD457.5 USD

113.0%

3.6%

1.9%

Price vs 50D9.3%

Price vs 200D24.9%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení má zkušenosti a společnost rozvíjí portfolio i akviziční strategii, avšak governance skóre ukazuje zvýšené obavy zejména v oblasti auditu a odměňování.

strong

Waters těží ze zavedených analytických technologií, odborného know-how a zákaznických nákladů na změnu přístrojů i navázaných spotřebních materiálů.

Information

Type: Global stock
Symbol: WAT
Exchange: NYSE
Currency: USD
Sector: Healthcare
: 109.4x
: 42.4B USD
: 36.1 %
: 1.15

§ Risk profile

Výsledky mohou kolísat s rozpočty farmaceutických firem a výzkumných laboratoří; odklady nákupů přístrojů mohou oslabit tržby. Český investor navíc podstupuje měnové riziko USD/CZK a riziko změny ocenění amerických akcií.

Ask the AI about Waters Corp.All signals